Document Detail


Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients.
MedLine Citation:
PMID:  20596795     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: There is a paucity of studies comparing stress ulcer prophylaxis (SUP) agents in high-risk neurosurgical patients.
METHODS: In this prospective, randomized study, critically ill neurosurgical patients received lansoprazole 30 mg suspension via NG/NJ tube daily or famotidine 20 mg IV q12 h for SUP. Gastric pH and residual volumes were recorded for 3 days and adverse events for 7 days after admission.
RESULTS: There were 51 patients randomized to lansoprazole (n = 28) or famotidine (n = 23) who received SUP for ≥ 3 days. All patients had at least two risk factors for SRMD, and 75% had a baseline GCS < 9. On day 1 of therapy, more famotidine patients had a gastric pH ≥ 4 at least 80% of the time as compared to lansoprazole patients (74 vs. 36%, P = 0.01, respectively); however, there was no difference on days 2 and 3. Enteral feedings on day 1 predicted a pH ≥ 4 (P = 0.01). There were no significant differences in the percentages of time gastric residual volumes < 28 ml (P = NS). Heme-positive aspirates were present in 18-39% of patients (P = NS); one patient receiving famotidine met the criteria for overt bleeding. Thrombocytopenia occurred in 17% in the famotidine group and 4% in the lansoprazole group (P = NS).
CONCLUSIONS: Neurosurgery ICU patients receiving famotidine for SUP achieved a gastric pH ≥ 4 more often than lansoprazole-treated patients, but only on day 1 of the 3-day study period. Both agents were equally effective in reducing gastric acid production. There was no difference in the incidence of mucosal damage and thrombocytopenia.
Authors:
Gretchen M Brophy; Marcia L Brackbill; Katherine L Bidwell; Donald F Brophy
Related Documents :
1742515 - A comparison of nizatidine and ranitidine in the maintenance treatment of duodenal ulce...
8906005 - A randomized, double blind, controlled trial of tocolysis to assist external cephalic v...
2688065 - A comparison of sucralfate and prednisolone enemas in the treatment of active distal ul...
2092025 - Long term behaviour of healed duodenal ulcer with and without maintenance therapy.
11032695 - Immediate and mid-term results of repeat percutaneous mitral commissurotomy for resteno...
9204355 - Iopentol (imagopaque 250) compared with diatrizoate (urografin 219) in endoscopic retro...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurocritical care     Volume:  13     ISSN:  1556-0961     ISO Abbreviation:  Neurocrit Care     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-22     Completed Date:  2011-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101156086     Medline TA:  Neurocrit Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  176-81     Citation Subset:  IM    
Affiliation:
Departments of Pharmacotherapy & Outcomes Sciences and Neurosurgery, Virginia Commonwealth University School of Pharmacy, P.O Box 980533, 410 N. 12th Street, Richmond, VA 23298, USA. gbrophy@vcu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage,  adverse effects,  therapeutic use*
Adult
Anti-Ulcer Agents / administration & dosage,  therapeutic use
Continental Population Groups
Critical Illness / therapy*
Famotidine / administration & dosage,  adverse effects,  therapeutic use*
Female
Gastric Acidity Determination
Gastric Juice / drug effects,  physiology
Gastrointestinal Hemorrhage / chemically induced,  epidemiology
Humans
Hydrogen-Ion Concentration
Injections, Intravenous
Male
Middle Aged
Neurosurgical Procedures
Prospective Studies
Suspensions
Young Adult
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Suspensions; 103577-45-3/lansoprazole; 76824-35-6/Famotidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Continuous and Intermittent CSF Diversion after Subarachnoid Hemorrhage: a Pilot Study.
Next Document:  Toll-like Receptors and Lupus Nephritis.